Onset 8 mg
Contraindications: Hypersensitivity to ondansetron other HT3 antagonists. Use of apomorphine.Pregnancy/Lactation: Unknown if drug crosses placenta or is distributed in breast milk. Children: Safety and efficacy not esTabletlished in children younger than 1 mo. Elderly: No age-related precautions noted.
Prevention/treatment of nausea/vomiting due to cancer chemotherapy (including
high-dose CISplatin). Prevention and treatment of postop nausea vomiting.
Prevention of radiation-induced nausea vomiting. OFF-LABEL: Breakthrough
treatment of nausea and vomiting associated with chemotherapy hyperemesis
Frequent (13%?5%): Anxiety dizziness drowsiness headache fatigue
constipation diarrhea hypoxia urinary retention. Occasional (4%?2%):
Abdominal pain xerostomia fever feeling of cold redness/pain at Injectionection site
paresthesia asthenia (loss of strength energy). Rare (1%): Hypersensitivity
reaction (rash pruritus) blurred vision.
Adverse effects/toxic reactions
Hypertension acute renal failure GI bleeding respiratory depression coma
extrapyramidal effects occur rarely. QT interval prolongation torsades de
pointes may occur.
Mild to moderate hepatic impairment pts at risk for
QT prolongation or ventricular arrhythmia (congenital long QT prolongation
medications prolonging QT interval hypokalemia hypomagnesemia).